139 related articles for article (PubMed ID: 26702804)
1. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States.
Danesh MJ; Kimball AB
J Am Acad Dermatol; 2016 Jan; 74(1):190-2. PubMed ID: 26702804
[No Abstract] [Full Text] [Related]
2. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
Lebwohl MG; Papp KA; Marangell LB; Koo J; Blauvelt A; Gooderham M; Wu JJ; Rastogi S; Harris S; Pillai R; Israel RJ
J Am Acad Dermatol; 2018 Jan; 78(1):81-89.e5. PubMed ID: 28985956
[TBL] [Abstract][Full Text] [Related]
3. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.
Chiricozzi A; Romanelli M; Saraceno R; Torres T
Expert Opin Drug Saf; 2016 Dec; 15(12):1653-1659. PubMed ID: 27554637
[TBL] [Abstract][Full Text] [Related]
4. A Closer Look at the Data Regarding Suicidal Ideation and Behavior in Psoriasis Patients: The Case of Brodalumab.
Rodriguez-Bolanos F; Gooderham M; Papp K
Skin Therapy Lett; 2019 Jul; 24(4):1-4. PubMed ID: 31339678
[TBL] [Abstract][Full Text] [Related]
5. New plaque psoriasis approval carries suicide warning.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248935
[No Abstract] [Full Text] [Related]
6. Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review.
Koo J; Ho RS; Thibodeaux Q
Cutis; 2019 Dec; 104(6):361-365. PubMed ID: 31939925
[TBL] [Abstract][Full Text] [Related]
7. Brodalumab for the treatment of psoriasis.
Galluzzo M; D'adamio S; Bianchi L; Talamonti M
Expert Rev Clin Immunol; 2016 Dec; 12(12):1255-1271. PubMed ID: 27718760
[TBL] [Abstract][Full Text] [Related]
8. Brodalumab: A Review of Safety.
Rusta-Sallehy S; Gooderham M; Papp K
Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
[TBL] [Abstract][Full Text] [Related]
9. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).
Blauvelt A; Papp KA; Lebwohl MG; Green LJ; Hsu S; Bhatt V; Rastogi S; Pillai R; Israel R
J Am Acad Dermatol; 2017 Aug; 77(2):372-374. PubMed ID: 28711089
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.
Galluzzo M; Talamonti M; D'adamio S; Bianchi L
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):679-691. PubMed ID: 28460549
[TBL] [Abstract][Full Text] [Related]
11. No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.
Strober BE; Langley RGB; Menter A; Magid M; Porter B; Fox T; Safi J; Papavassilis C
Br J Dermatol; 2018 Feb; 178(2):e105-e107. PubMed ID: 28991372
[No Abstract] [Full Text] [Related]
12. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
14. What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab.
Hashim PW; Chen T; Lebwohl MG; Marangell LB; Kircik LH
J Drugs Dermatol; 2018 Aug; 17(8):s29-s34. PubMed ID: 30124737
[TBL] [Abstract][Full Text] [Related]
15. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
Schmidt C
Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
[TBL] [Abstract][Full Text] [Related]
17. Suicidal behavior during economic hard times.
Elliott M; Naphan DE; Kohlenberg BL
Int J Soc Psychiatry; 2015 Aug; 61(5):492-7. PubMed ID: 25359733
[TBL] [Abstract][Full Text] [Related]
18. Economic recession and suicidal behaviour: Possible mechanisms and ameliorating factors.
Haw C; Hawton K; Gunnell D; Platt S
Int J Soc Psychiatry; 2015 Feb; 61(1):73-81. PubMed ID: 24903684
[TBL] [Abstract][Full Text] [Related]
19. COSENTYX (Secukinumab).
Gupta AK; Foley KA; Abramovits W
Skinmed; 2015; 13(4):303-6. PubMed ID: 26861430
[No Abstract] [Full Text] [Related]
20. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.
Endres CJ; Salinger DH; Köck K; Gastonguay MR; Martin DA; Klekotka P; Nirula A; Gibbs MA
J Clin Pharmacol; 2014 Nov; 54(11):1230-8. PubMed ID: 24846347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
